Cohance Lifesciences Limited — Board Meeting, 05-08-2026: Outcome of Board Meeting

Cohance Lifesciences' board approved Q1 results, reporting ₹422.3 Cr revenue and ₹43 Cr adjusted loss. The company plans to acquire full ownership of Sapala Organics, integrating its nucleic-acid business under Dr. P. Yella Reddy's leadership. An AGM is set for Sept 17, with management expecting growth to rebound in H2.